3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Endocrine
1
Conditions
Neuroendocrine Tumors
74
Carcinoma, Neuroendocrine
28
Pheochromocytoma
24
Thyroid Cancer, Papillary
23
Pituitary Neoplasms
22
Thyroid Neoplasms
21
Adrenocortical Carcinoma
19
Paraganglioma
16
Multiple Endocrine Neoplasia Type 1
14
Sarcoma
11
Neuroblastoma
11
Small Cell Lung Carcinoma
10
Neoplasms
10
Adenoma, Islet Cell
10
Melanoma
9
Lung Neoplasms
9
Carcinoid Tumor
9
Adrenal Gland Neoplasms
9
Adenocarcinoma, Follicular
9
Pancreatic Neoplasms
8
Gastro-enteropancreatic neuroendocrine tumor
8
Carcinoma, Non-Small-Cell Lung
8
Carcinoma, Medullary
8
Breast Neoplasms
8
Thyroid Carcinoma, Anaplastic
7
Ovarian Neoplasms
7
Neoplasm Metastasis
7
Cushing Syndrome
7
Cholangiocarcinoma
7
Central Nervous System Neoplasms
7
Interventions
trametinib
1
dabrafenib
1
Thyrotropin Alfa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
×
Endocrine
×
90 days
×
Clear all
NCT03244956
2026-03-23
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2
Completed
40 enrolled